PUBLICATIONS MOST RELEVANT RECENT PUBLICATIONS 1.

PUBLICATIONS
MOST RELEVANT RECENT PUBLICATIONS
1. A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes. Haibe-Kains B,
Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J, Sotiriou C. J Natl Cancer Inst. 2012
Jan 18. [Epub ahead of print]
2. Elucidating prognosis and biology of breast cancer arising in young women using gene
expression profiling. Azim H, Michiels S, Bedard PL, Singhal SK, Criscitiello C, Ignatiadis M,
Haibe-Kains B, Piccart MJ, Sotiriou C, Loi S. Clin Cancer Res. 2012 Jan 18. [Epub ahead of print]
3. Characterization and clinical evaluation of CD10+ stroma cells in the breast cancer
microenvironment. Desmedt C, Majjaj S, Kheddoumi N, Singhal SK, Haibe-Kains B, El Ouriaghli
F, Chaboteaux C, Michiels S, Lallemand F, Journe F, Loi S, Quackenbush J, Duvillier H, Dekoninck
S, Blanpain C, Lagneaux L, Houhou N, Delorenzi M, Larsimont DP, Piccart MJ, Sotiriou C. Clin
Cancer Res. 2012 Jan 10. [Epub ahead of print]
4. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens
as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Di Leo A,
Desmedt C, Bartlett JM, Piette F, Ejlertsen B, Pritchard KI, Larsimont D, Poole C, Isola J, Earl H,
Mouridsen H, O'Malley FP, Cardoso F, Tanner M, Munro A, Twelves CJ, Sotiriou C, Shepherd L,
Cameron D, Piccart MJ, Buyse M; for the HER2/TOP2A Meta-analysis Study Group. Lancet
Oncol. 2011 Sep 12.
5. DNA methylation profiling reveals a predominant immune component in breast cancers.
Dedeurwaerder S, Desmedt C, Calonne E, Singha SK, Haibe-Kains B, Defrance M, Michiels S,
Volkmar M, Deplus R, Luciani J, Lallemand F, Larsimont D, Toussaint J, Haussy S, Rothé F, Rouas
G, Metzger O, Majjaj S, Saini K, Putmans P, Hames G, Baren NV, Coulie PG, Piccart M, Sotiriou C,
Fuks F. EMBO Mol Med. 2011 Sep 12. doi: 10.1002/emmm.201100801.
6. Global MicroRNA Expression Profiling Identifies MiR-210 Associated with Tumor Proliferation,
Invasion and Poor Clinical Outcome in Breast Cancer. Rothé F., Ignatiadis M., Chaboteaux C.,
Haibe-Kains B. , Kheddoumi N., Majjaj S., Badran B.3, Fayyad-Kazan H., Desmedt C. , Harris A.L.,
Piccart M., Sotiriou C. PLoS One. 2011;6(6):e20980. Epub 2011 Jun 29.
7. Multifactorial Approach to Predicting Resistance to Anthracyclines. Desmedt C, Di Leo A, de
Azambuja E, Larsimont D, Haibe-Kains B, Selleslags J, Delaloge S, Duhem C, Kains JP, Carly B,
Maerevoet M, Vindevoghel A, Rouas G, Lallemand F, Durbecq V, Cardoso F, Salgado R, Rovere R,
Bontempi G, Michiels S, Buyse M, Nogaret JM, Qi Y, Symmans F, Pusztai L, D'Hondt V, Piccart-
Gebhart M, Sotiriou C. J Clin Oncol. 2011 Apr 20; 29 (12): 1578-86. Epub 2011 Mar 21.
8. Genomic Index of Sensitivity to Endocrine Therapy for Breast Cancer. W. Fraser-Symmans, C.
Hatzis, C. Sotiriou, F. André, F. Peintinger, P. Regitnig, G. Daxenbichler, C. Desmedt, J. Domont,
C. Marth, S. Delaloge, T. Bauernhofer, V. Valero, D. J. Booser, G. N. Hortobagyi. L. Pusztai. J Clin
Oncol, 2010 Sept; 28(27): 4111-9.
9. PIK3CA mutations associated with gene signature of low mTORC1 signaling and better
outcomes in breast cancer. S. Loi, B. Haibe-Kains, F. Lallemand, S. Majjaj, V. Durbecq, D.
Larsimont, A M Gonzalez-Angulo, L. Pusztai, W. Fraser-Symmans, A. Bardelli, P. Ellis, A. NJ Tutt,
C. E. Gillett, G. B. Milles, B. T Hennessy, W.A. Phillips, T. P. Speed, MJ Piccart, G. A. McArthru, C.
Sotiriou. Proc Natl Acad Sci U S A (IF: 9.380). 2010 Jun 1; 107(22):10208-13.
10. International network of cancer genome projects. International Cancer Genome Consortium.
Nature. 2010 Apr 15; 464 (7291):993-8.
11. Assessment of an RNA Interference Screen-Derived Mitotic and Ceramide Pathway Metagene
as a Predictor of Response to Neoadjuvant Paclitaxel for Primary Triple-Negative Breast
Cancer: a Retrospective Analysis of Five Clinical Trials. Juul N, Szallasi Z, Eklund AC, Li Q, Burrell

RA, Gerlinger M, Valero V, Andreopoulou E, Esteva FJ, Symmans WF, Desmedt C, Haibe-Kains B,
Sotiriou C, Pusztai L, Swanton C. Lancet Oncol. 2010 Apr; 11(4): 358-65.
12. Molecular profiling of CD3-CD4+ T cells from patients with the lymphocytic variant of
hypereosinophilic syndrome reveals targeting of growth control pathways. Ravoet M, Sibille C,
Gu C, Libin M, Haibe-Kains B, Sotiriou C, Goldman M, Roufosse F, Willard-Gallo K. Blood, 2009
Jul 16.
13. Genomic grade index is associated with response to chemotherapy in patients with breast
cancer. Liedtke C, Hatzis C, Symmans WF, Desmedt C, Haibe-Kains B, Valero V, Kuerer H,
Hortobagyi GN, Piccart-Gebhart M, Sotiriou C, Pusztai L. J Clin Onco, 2009 Jul 1;27(19):3185-91.
14. Gene-expression signatures in breast cancer. Sotiriou C, Pusztai L. N Engl J Med (IF: 50.017),
2009 Feb 19; 360(8):790-800.
15. Biological processes associated with breast cancer clinical outcome depend on the molecular
subtypes. Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi
M, Piccart M, Sotiriou C. Clin Cancer Res, 2008 Aug 15;14(16):5158-65.
16. Meta-analysis of gene expression profiles in breast cancer: toward a unified understanding of
breast cancer subtyping and prognosis signatures. Wirapati P, Sotiriou C, Kunkel S, Farmer P,
Pradervand S, Haibe-Kains B, Desmedt C, Ignatiadis M, Sengstag T, Schütz F, Goldstein DR,
Piccart M, Delorenzi M. Breast Cancer Res , 2008;10(4):R65.
17. A five-gene molecular grade index and HOXB13:IL17BR are complementary prognostic factors
in early stage breast cancer. Ma XJ, Salunga R, Dahiya S, Wang W, Carney E, Durbecq V, Harris
A, Goss P, Sotiriou C, Erlander M, Sgroi D. Clin Cancer Res, 2008 May 1;14(9):2601-8.
18. Taking gene-expression profiling to the clinic: when will molecular signatures become
relevant to patient care? Sotiriou C, Piccart MJ. Nat Rev Cancer, 2007 Jul;7(7):545-53.
19. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer
patients in the TRANSBIG multicenter independent validation series. Desmedt C, Piette F, Loi S,
Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, Bergh J,
Lidereau R, Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C;
TRANSBIG Consortium. Clin Cancer Res, 2007 Jun 1;13(11):3207-14.
20. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast
carcinomas through genomic grade. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM,
Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G,
Delorenzi M, Piccart MJ, Sotiriou C. J Clin Oncol , 2007 Apr 1;25(10):1239-46.
21. Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-
expression profiling study. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA,
Valero V, Booser D, Pippen JE Jr, Vukelja S, Gomez H, Mejia J, Barajas LJ, Hess KR, Sneige N,
Hortobagyi GN, Pusztai L, Symmans WF. Lancet Oncol (IF: 13.383), 2007 Mar;8(3):203-11.
22. Validation and clinical utility of a 70-gene prognostic signature for women with node-
negative breast cancer. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies
MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F,
Rutgers E, Sotiriou C, Cardoso F, Piccart MJ; TRANSBIG Consortium. J Natl Cancer Inst, 2006 Sep
6; 98(17): 1183-92.
23. Gene expression profiling in breast cancer: understanding the molecular basis of histologic
grade to improve prognosis. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H,
Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse
M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M. J Natl Cancer Inst, 2006 Feb 15;98(4):262-
72.
24. Breast cancer classification and prognosis based on gene expression profiles from a
population-based study. Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, Martiat
P, Fox SB, Harris AL, Liu ET. Proc Natl Acad Sci U S A, 2003 Sep 2; 100(18):10393-8.